Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4279298
Max Phase: Preclinical
Molecular Formula: C29H35N5O3
Molecular Weight: 501.63
Molecule Type: Small molecule
Associated Items:
ID: ALA4279298
Max Phase: Preclinical
Molecular Formula: C29H35N5O3
Molecular Weight: 501.63
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C=C(C)[C@@H]1CC=C(Cn2cc(COc3cccc(C4NC(=O)NC5=C4C(=O)CC(C)(C)C5)c3)nn2)CC1
Standard InChI: InChI=1S/C29H35N5O3/c1-18(2)20-10-8-19(9-11-20)15-34-16-22(32-33-34)17-37-23-7-5-6-21(12-23)27-26-24(30-28(36)31-27)13-29(3,4)14-25(26)35/h5-8,12,16,20,27H,1,9-11,13-15,17H2,2-4H3,(H2,30,31,36)/t20-,27?/m1/s1
Standard InChI Key: NZXJLBZCWSKVCV-ACVCQEAVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 501.63 | Molecular Weight (Monoisotopic): 501.2740 | AlogP: 5.16 | #Rotatable Bonds: 7 |
Polar Surface Area: 98.14 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 8 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.56 | CX Basic pKa: | CX LogP: 3.89 | CX LogD: 3.89 |
Aromatic Rings: 2 | Heavy Atoms: 37 | QED Weighted: 0.51 | Np Likeness Score: -0.65 |
1. Vendrusculo V, de Souza VP, M Fontoura LA, M D'Oca MG, Banzato TP, Monteiro PA, Pilli RA, de Carvalho JE, Russowsky D.. (2018) Synthesis of novel perillyl-dihydropyrimidinone hybrids designed for antiproliferative activity., 9 (9): [PMID:30288229] [10.1039/C8MD00270C] |
Source(1):